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Background. The determination of the safety proﬁle of any vaccine is critical to its widespread use in any
population. In addition, the application of international guidelines to ﬁt local context could be a challenging but
important step toward obtaining quality safety data.
Methods. In clinical studies of PsA-TT (MenAfriVac), safety was monitored immediately after vaccination, at
4–7 days for postimmunization local and systemic reactions, within 28 days for adverse events, and throughout the
duration of study for serious adverse events. Initial and ongoing training of sites’ staff were undertaken during the
studies, and a data and safety monitoring board reviewed all the data during and after the studies.
Results. The safety of PsA-TT was evaluated according to international standards despite obvious challenges in
remote areas where these studies were conducted. These challenges included the need for uniformity of methods,
timely reporting in the context of frequent communication problems, occurrence of seasonal diseases such as malaria
and rotavirus diarrhea, and healthcare systems that required improvement.
Conclusions. The trials of PsA-TT highlighted the value of a robust vaccine development plan and design so that
lessons learned in initial studies were incorporated into the subsequent ones, initial training and periodic retraining,
strict monitoring of all procedures, and continuous channel of communication with all stakeholders that enabled the
application of international requirements to local settings, with high quality of data.
Keywords. MenAfriVac; safety monitoring and reporting; uniform methods; effective communication.
Determination of the safety proﬁle of any vaccine or
drug is crucial before its routine utilization in the
community, as drugs that show a safe proﬁle in animal
studies can show a different effect in humans [1]. Ap-
propriate study designs and study sizes are needed to
determine both short- and long-term safety [2]. In the
1990s, the use of high-dose measles vaccine was associ-
ated with increased mortality in females, a ﬁnding that
led the World Health Organization (WHO) to rescind
its earlier recommendation on the vaccine [3, 4]. Al-
though scientists scrambled to explain the reason for
such an unusual ﬁnding, it further emphasized the
need for due diligence in assessing the safety of any vac-
cine before it can be introduced into the population
[3, 5]. There was a similar occurrence with the ﬁrst
oral rotavirus vaccine [6].
Following the introduction of Haemophilus inﬂuen-
zae type b (Hib) conjugate, there were reports of occur-
rence of Guillain-Barré syndrome (GBS) [7, 8]. In a
rather more dramatic fashion, rare cases of GBS were
also reported in the United States in a temporal rela-
tionship following administration of Menactra [9]. Al-
though several hypotheses have been propounded to
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explain the possible occurrence of GBS following immunization
[8, 10], comparison with expected rates of GBS has been incon-
clusive to deﬁne if there is increased risk of GBS with the ad-
ministration of diphtheria, tetanus, polio, Hib combination
vaccine, and quadrivalent meningococcal conjugate vaccine
[10, 11]. Taken together, these ﬁndings highlight the need for
due rigor in establishment of the safety proﬁle of any vaccine.
Thus, the trials for PsA-TT (MenAfriVac) were designed to en-
sure that both common and rare adverse events (AEs) were de-
tectable throughout the clinical development period.
DESIGN OF SAFETY COMPONENT OF VACCINE
TRIALS AND RATIONALE
Eight clinical trials were conducted in groups ranging from 14
weeks to 29 years of age, in 5 countries (India, Gambia, Mali,
Senegal, and Ghana) during the clinical development of PsA-
TT. These trials were double-blind randomized controlled stud-
ies designed to allow adequate comparison of the safety proﬁle
of PsA-TT with that of 2 licensed vaccines; some of the results
have been reported elsewhere [12].
Group A Neisseria meningitidis infections occur across vari-
ous regions and cultures with heterogeneous characteristics. In
the design of the safety component of the trials of PsA-TT, uni-
form system and harmonized procedures were used to collect
the data, while making allowance for peculiarities in each of
the settings where the studies were done. This was necessary
to ease combination of the data sets and comparison of speciﬁc
characteristics between groups as the trials took place in several
areas with cultural and geographic variations. These trials also
complied with the Good Clinical Practice (GCP) standard and
other international regulatory requirements.
DESCRIPTION OF METHODS OF SAFETY
ASSESSMENT
Across all the trials, safety assessments were done at speciﬁed
time points as per standard operating procedures (SOPs)
from the sponsors and the sites.
Immediate Safety Assessment
The purpose of this was to detect any adverse reactions that
occur immediately after administration of the study vaccine.
Subjects were observed before the vaccination and then after
vaccination for between 30 minutes and 60 minutes. During
this period, subjects were assessed for any AE or any immediate
hypersensitivity reaction. The injection site was also examined
for any local reaction such as induration or tenderness.
Postimmunization Local and Systemic Reaction Monitoring
Participants were visited daily for 4 days (7 days in the initial
studies) to document any systemic or local reaction. The
follow-up on day 4 (or 7) was done by a medical doctor. A
consistent method of soliciting systemic reactions was used,
and the participants or their caregivers were asked nonleading
questions. Any solicited systemic reactions were recorded, and
the injection site was examined to document any local reaction
such as tenderness and induration. Study staff assessed the in-
tensity of the tenderness using a priori–deﬁned grading crite-
ria. The size of any induration and temperature were also
measured.
Recording of Adverse Events
Untoward medical occurrences were recorded from the date of
vaccine administration until 28 days following vaccination. The
diagnosis, date of onset, intensity, and treatment given were re-
corded. As much as possible, these AEs were deﬁned in terms of
diagnosis, but if this was not possible, symptomatic AEs were
documented. Medical doctors assessed the causality of AEs
based on priori–deﬁned criteria (see below).
Recording of Serious Adverse Events
As per International Conference on Harmonisation (ICH)
guidelines [13], a serious adverse event (SAE) was deﬁned as
an untoward medical occurrence that results in death, is life
threatening, results in persistent or signiﬁcant disability/
incapacity, requires inpatient hospitalization or prolongation
of existing hospitalization, is a congenital anomaly/birth defect
in the offspring of a study subject, or is an important medical
event that may jeopardize the subject or may require interven-
tion to prevent one of the other serious outcomes. These were
identiﬁed and documented by the investigators, who were re-
sponsible for appropriate care for the subjects and timely
reporting of the SAEs. The recording of SAEs started immedi-
ately, when the subject was enrolled in the study, and continued
until the end of the study. The intensity of any SAE was assessed
using predeﬁned criteria; the treatment given and the outcome
of the event were documented in the case report form.
ASSESSMENT OF CAUSALITY
Before the start of the PsA-TT studies, it was decided that any
solicited event elicited within the ﬁrst 4 (or 7) days after vac-
cination would be regarded as an adverse reaction—that is,
they would be assumed to be caused by study vaccines. This
decision eases the difﬁculty that might occur in assigning cau-
sality immediately after the study vaccine was given, but is
mindful of the fact that many may not be related to the
study vaccine. The assessment of causality for other AEs or
SAEs was based on 3 deﬁned considerations: the temporal re-
lationship of the event to the time the study vaccine was given;
the possibility of other obvious causes; and the previous AE
experience of the study vaccine or other similar conjugate vac-
cines as speciﬁed in the Investigator’s Brochure. In all PsA-TT
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trials, conforming to current practice in clinical development,
only 2 grades were used for the assessment of causality: related
and unrelated.
TRAINING
A very important component of the AE and SAE monitoring
was the rigor taken in training all those involved in the studies.
Trainings included basic GCP training, training on the protocol
and SOPs, and practically veriﬁed training on procedures. Nurs-
es and ﬁeld workers received bedside training on identiﬁcation
of common clinical signs, assessment of intensity, and measure-
ment of dimensions of local reactions. Physicians were also
trained to ensure uniformity in the ascertainment of clinical
signs and assigning causality. In some studies, parents and sub-
jects were trained to document AEs. These trainings were done
at the beginning of each study, and at speciﬁed milestones—for
instance, after recruitment of a speciﬁed percentage of the sam-
ple size. There were also in-built, ongoing, on-the-job trainings
through periodic monthly or fortnightly business meetings and
person-to-person interaction. Data on error rate and common
errors were regularly generated at the study sites to facilitate
these trainings.
REPORTING OF SERIOUS ADVERSE EVENTS
A simple reporting system of AEs and SAEs (Figure 1) was em-
ployed in the PsA-TT clinical trials. Investigators reported all
SAEs to the Contract Research Organization (CRO), which re-
ported to the sponsors. The sponsors (or their agent) in turn
reported the SAEs to the data and safety monitoring board
(DSMB) and various ethics review committees and regulatory
authorities. The investigators also reported the SAEs to the
local ethics review committees. As the study progressed, there
was an accumulation of experiences and innovation that helped
to simplify the system. At the site, speciﬁc staff was designated
to be in charge of all SAE communications. This helped to de-
crease errors and ensured that each SAE was properly docu-
mented, tracked, and followed up in accordance with speciﬁed
timelines.
During the earlier phases of the PsA-TT trials, SAEs were re-
ported with handwritten forms. As the studies progressed, to
comply with the Council for International Organizations of
Medical Sciences reporting system [14], recording of AE data
on an electronic template was introduced. This made the pro-
cess more efﬁcient, and any new information was highlighted to
ease identiﬁcation. Designated staff was put in charge of this
Figure 1. Adverse events and serious adverse events (SAE) reporting system for PsA-TT trials (MenAfriVac). Abbreviations: AARSH, Agence Africaine de
Recherche en Santé Humaine (monitors); DSLS, DiagnoSearch Life Sciences (pharmacovigilance coordination); DSMB, data and safety monitoring board;
IRB, institutional review board; MVP, Meningitis Vaccine Project; SIIL, Serum Institute of India, Ltd. (vaccine manufacturers); WHO/ERC, World Health
Organization Ethic Review Committee; WIRB, Western Institute Review Board.
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To ensure the collection of valid data, there was a culture of mon-
itoring from the ﬁeld sites up to the level of the DSMB. Investiga-
tors monitored one another to ensure the accuracy, completeness
of AE forms, and also timeliness of the SAE reporting. SAE re-
ports were checked for accuracy and compliance with the protocol
by the responsible CRO. A different CRO performed periodic
monitoring visits to the study sites, where they compared the
source documents with what was recorded on the SAE report
forms and/or case report forms, to reconcile any discrepancy.
The frequency of the visits was determined by the nature of the
study and the quantity of data to be monitored. The sponsors also
employed the services of an experienced safety consultant who
helped set up the SAE system and during the course of studies
clariﬁed terms and important dates and resolved differences in
understanding.
Role of DSMB
ADSMB of 3–4 experts was set up prior to initiation of each PsA-
TT clinical trial in accordance with GCP requirements and the
DSMB charter. These comprised distinguished epidemiologists,
pediatricians, and a respected lay member of the community.
For each study, there was a mixture of international and local ex-
perts. The group conducted face-to-face meetings or telephone
conferences, and thoroughly assessed the data during the course
of each study, providing the sponsors with overall review of the
study to ensure adequate protection of study subjects. The board
reviewed SAE reports and all AEs at speciﬁed intervals and ad-
vised the sponsors on any concerns in relation to the vaccine
safety, in addition to making appropriate recommendations. Im-
portant safety-related activities or study participants’ health is-
sues were reviewed with the DSMB, and the advice was taken
into consideration in decisions related to these issues.
Role of Periodic Meetings
Early on in the clinical development, it was noted that under-
standing of issues and SOP items varied across trial sites. This
was not surprising, considering the wide cultural differences in
the different places where the studies took place. Efforts were
made to harmonize these differences so as not to jeopardize sub-
jects’ health. Periodic meetings were set up between the sites and
sponsors; sites and CRO; and sites, CRO, and sponsors to discuss
any misunderstanding, misinterpretation, and challenges to en-
sure a common understanding and practice. When necessary,
further trainings were organized at the sites to improve the un-
derstanding and implementation of speciﬁc aspects of the SOP.
Also during the course of each trial, meetings were set up to clar-
ify issues such as SAE onset date, end date, and any issue with the
reporting system. Each of the different collaborators could trigger
a meeting, although sponsors bore the overall responsibility for




Because harmonized understanding and ascertainment proce-
dures for safety assessment were crucial in view of diverse cul-
tural, linguistic, and religious environments, extra efforts were
made to meet this standard. Much effort was invested in ensur-
ing uniform translations of the study documents and under-
standing by study workers. Close monitoring of the data
collected helped to detect misunderstanding (eg, between
“swelling” and “induration”), which was tackled by further
training, demonstration, and the development of a ﬁeld manual
for a “ballpoint” measuring technique [15]. Similarly, an issue
was observed in one of the study sites in relation to deﬁning
the onset date of SAEs and a hospital stay that fulﬁlled the in-
patient hospitalization criterion. At this site, subjects preferred
to be treated as outpatients rather than being admitted, and oth-
ers wanted to be put on parenteral medication even when the
doctor did not think this necessary. The SOP for this site was
revised to accommodate this peculiar environment. Periodic
meetings were held to ensure that the safety of subjects was
not jeopardized. Relevant dates were clearly deﬁned.
It is common practice in some of our study sites to give chil-
dren antipyretics before or following immunization. As this
may have an impact on the immune responses following immu-
nization [16, 17], effort was made to document this, and the an-
alytical plan provided for a comparison between those who
received and those who did not receive antipyretics.
Timely Reporting
The studies were performed in rural, suburban, and urban en-
vironments with varying communication challenges such as
unreliable email network, phone outage, and time differences.
There were in-built plans to communicate both internally for
the study and with external collaborators and agencies. SOPs
clearly speciﬁed what to do depending on the circumstance.
Study staff used telephone to communicate with subjects or
their parent/guardian, and for reporting of AEs to responsible
staff. Responsible staff used either email or fax or telephone
to report SAEs to the CRO, the sponsors, or the relevant review
boards. When email or fax did not work, SAE reports were ﬁrst
communicated by telephone, and the copy was sent as soon as
the appropriate communication line was reestablished. Time-
lines were followed, and any lateness was addressed by the
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designated coordinator. To ensure that timelines could be kept,
minimum information for initial reporting was required as de-
ﬁned by ICH GCP; this included subject identity, the reporter,
time of vaccination, date, and description of event with prelim-
inary assessment of severity and causality. Follow-up reports
were generated when new information became available. To en-
sure effectiveness, timelines for conclusions of SAE reports were
speciﬁed, and every effort was made to stick to these timelines.
Lists were generated regularly as a reminder for pending SAE
reports and/or summary SAE narratives.
Differences in Ethical and Regulatory Reporting Requirements
PsA-TT clinical trials had to comply with different approval and
reporting systems in sub-Saharan African countries and India in
line with GCP. Approval was sought from various regulatory
bodies, local ethics review committees, and institutional review
boards of partner institutions. As expected, the requirements
for these committees varied, and the studies had to work hard
to harmonize diversities. For instance, although some commit-
tees were satisﬁed withmonthly summary reports, some commit-
tees requested an expedited reporting of all SAEs, whether related
or not related to the study vaccine, in addition to the monthly
summary reports. This unusual directive was particularly chal-
lenging to the study site, more so when receipt of most of these
transmissions was not acknowledged by the regulatory body.
However, every effort was made to comply with them.
Health Systems in Different Study Sites
PsA-TT clinical trials were conducted in rural areas and cities
with varying degrees of functional health systems. One of the
important questions in conduct of clinical trials in developing
countries is what type of medical care should be given to
study subjects [16]. Should this be according to the local med-
ical practice or according to the best international practice? In
most rural areas, there were stafﬁng challenges, and various lev-
els of inadequacies including partially functional laboratory fa-
cilities. Case ascertainment of events thus required appropriate
training across sites to ensure uniformity. Moreover, country-
speciﬁc treatment policies are tailored according to each
country’s socioeconomic environment. Medical monitors had
to resolve conﬂicts arising from what they knew regarding nor-
mal practice in the local environment. Copies of these policies
were obtained for references, and they became the yardsticks to
assess what was appropriate for any given case.
In some study sites, a peculiar health system operated that
had the use of traditional medications, homeopathic therapy,
and orthodox drugs accepted ofﬁcially. Due to the conﬁdence
that many of people from developing countries place in tradi-
tional medicines, at times it was difﬁcult to control their use
or even to know what medicine a subject actually received. In
certain situations, different types of therapy were given together
to a study subject. In other situations, the subjects took these
themselves, even after receiving the drugs prescribed by study
staff. All possible efforts were made to document this and to
code with WHO Drug Dictionary.
Seasonal Diseases and Epidemics Not Related to the Study
Disease
The so-called African meningitis belt, which stretches from
Dakar in the west to Ethiopia in the east, is also an endemic ma-
laria environment [18]. Malaria is seasonal, and during this pe-
riod there were increased numbers of SAEs due to malaria,
especially in the studies that involved infants and toddlers. Al-
though a priori criteria stipulated that subjects with signiﬁcant
ill health were temporarily exempted from receiving any vac-
cine, at times it was difﬁcult to diagnose accurately as clinical
malaria can be both sudden and dramatic. Although the labo-
ratory conﬁrmation of malaria in most cases helped to distin-
guish it from the vaccine AEs, in some cases, this was difﬁcult.
At a site where one of the infant studies was conducted, Oc-
tober to February is a known rotavirus diarrhea season. As ro-
tavirus is the commonest cause of diarrhea in infants, there were
a number of SAEs of acute watery diarrhea. Fortunately, during
the same period, there was ongoing rotavirus surveillance, and
this helped to conﬁrm rotavirus infection in most of these cases.
Safety Evaluation for the Future
Pregnant and lactating women constitute an important group in
the community. According to ICH guidelines, pregnant women
should be excluded from clinical trials where the drug is not in-
tended for use in pregnancy [13].The guidance also states that ex-
cretion of drug or its metabolites should be monitored in breast
milk and infants should be monitored for effects of drugs. These
guidelines are issued due to the vulnerability of the developing
fetus and infants to the effect of drugs, which is often complex.
However in real life, many drugs are prescribed to pregnant
women and lactating mothers when the beneﬁt of the drug far
outweighs the risk of possible adverse effects. In the PsA-TT trials,
none of the studies were designed to assess the safety of the vac-
cine in pregnant and nursing mothers, and women of childbear-
ing age were advised to use adequate contraception. However,
when some subjects inadvertently became pregnant, they were
monitored until delivery, and any events in the mother or the
newborn were documented. Because women of childbearing age
are susceptible to group Ameningococcal disease, this raised a di-
lemma. Consequently, a detailed risk-beneﬁt analysis was con-
ducted, based on burden and impact of the disease in pregnant
women, data from nonclinical studies, and experience with simi-
lar vaccines, which justiﬁed the use of the vaccine in pregnant
women during the postlicensure use of the vaccine [19].
PsA-TT (MenAfriVac) has now been given postlicensure to
>217 million people aged 1–29 years [20]; hence, women of
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childbearing age constitute a signiﬁcant proportion. A study
follows up the safety of MenAfriVac in pregnant women and
pregnancy outcomes, and data conﬁrm that the vaccine has
no adverse effect on pregnant women and their infants [21].
CONCLUSIONS
Rigorous procedures as required by GCP standards were
followed in all the clinical studies to monitor the safety of
PsA-TT as well as to ensure safety of the study participants.
The following key lessons were learned in the process: (1) It is
important to have a robust vaccine development plan and design
so that lessons learned in initial studies can be incorporated into
subsequent studies; (2) initial training, but crucially also periodic
retraining, of all study staff on the protocol and the SOPs is im-
portant; (3) strict monitoring of procedures, documentation,
and reporting are very beneﬁcial to evaluate the safety of a
new vaccine; and (4) a continuous channel of communication
with all stakeholders enables the application of international re-
quirements to local settings, with appropriate quality.
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